Clinical Trials | A Phase 1b/2 Open-label Study Evaluating different MK-6070 and Ifinatamab Deruxtecan (MK-2400)-based regimens in First-line Extensive Stage Small Cell Lung Cancer

The University of Virginia Comprehensive Cancer Center seeks participants ages 18 and over with Extensive Stage Small Cell Lung Cancer (ES-SCLC) that have received no prior systemic therapy for their disease or has only been treated with certain standard treatments. The purpose of this study is to: • Test the safety of the trial treatment combinations • See how well the trial treatment combinations work • Measure how the immune system reacts to MK-6070 and I-DXd • Measure what happens as MK-6070 and I-DXd go through the body This study will take place in two parts: A and B. Part A is being done to find recommended doses of I-DXd and MK-6070 when given together for further testing in this trial. Part B will begin once the recommended doses for further testing in this trial are decided. The study doctor will tell you which part you are in. In Part B of this study, if you got standard treatments for ES-SCLC before joining the trial, you will be put in Group 1: Group 1 will get MK-6070 and I-DXd. If you did not get standard treatments for ES-SCLC before joining the trial, you will be assigned to 1 of 3 trial treatment plans. A computer will randomly decide your trial treatment (like flipping a coin). You have an equal chance of being put into any of the groups: Group 2 will get MK 6070 and I-DXd. Group 3 will get MK-6070 and I-DXd followed by MK-6070 and atezolizumab. Group 4 will get carboplatin, etoposide, and atezolizumab followed by atezolizumab. The Screening Phase and will last about 1 month. During this time, you will visit the site 1 or more times. Then, as long as you are getting trial drugs you will visit the trial site about 1 time every 3 weeks. After you have completed your follow-up visits, the trial doctor or staff may contact you about every 3 months, or more frequently, to check on your health. You may or may not benefit as a result of your participation in this study. However, this study may also help doctors learn things that can help other people in the future. For questions, contact: [email protected]